Genetic Signatures Ltd (GSS) fair value: what the stock is really worth
As of Nov 9, 2026: fair value (intrinsic value) of Genetic Signatures Ltd stock A$0.12, price A$0.07, upside +83.3%, quality 35 out of 100. Rating: strongly undervalued. Calculated from audited financials with one of our 26 valuation models and 37 quality factors, updated daily.
69 individual criteria per stock, every one traceableSee the method →
Price vs Fair Value
White line = price, green steps = our fair value per fiscal year. As of Nov 4, 2026.
How to read this chart
60‑month range A$0.0560 – A$1.75 · fair‑value band A$0.0866 – A$0.1550 · the A$0.0680 price screens below the A$0.1246 fair value. Green steps = our fair value per fiscal year (point-in-time, no hindsight). As of Nov 4, 2026.
Follow Genetic Signatures in your weekly email
Every Wednesday you see whether Genetic Signatures is on track or worth a review, plus price against fair value. Free, up to 3 stocks.
We send you a confirmation link. Unsubscribe with one click.
Genetic Signatures Limited operates as a molecular diagnostic company in Australia, the Asia Pacific, Europe, the Middle East, Asia, and the Americas.
Show moreShow less
It offers enteric bacteria, Enteroaggregative E.coli aggR and aaiC, enteric viral, enteric protozoan, enteric protozoan extended, enteric microsporidia, respiratory pathogen, SARS-CoV-2, extended respiratory, atypical respiratory, Measles, Mumps, and Rubella detection kits under the EasyScreen name.
The company was incorporated in 2001 and is headquartered in Newtown, Australia.
Stock analysis
Genetic Signatures Ltd (GSS) currently trades at A$0.0680, while our model-based Fair Value estimate is A$0.1246, implying the stock looks roughly 45% undervalued today.
Show more
Valuation
How firm this estimate is: it rests on 1 models at a data quality of 96/100, which puts the data coverage at low.
Scenario range: A$0.0866 (bear) to A$0.1550 (bull), the price of A$0.0680 sits below it. Bear and bull are the same models on cautious and optimistic assumptions, a range, not a price target.
Quality & growth
The Quality Score stands at 35/100 (below-average quality), in the Healthcare sector.
Weak Growth: Revenue is shrinking: the last year, the last three and the last five years are all negative.
Genetic Signatures Ltd reported revenue of A$14.5M in FY2026 versus A$35.4M in FY2022, a compound −20.1%/yr. Reported net income was −A$14.0M in FY2026.
Key figures
Market cap A$15.4M (≈ $10.6M) Micro · P/S ratio 0.93 · EPS (TTM) A$−0.0600 · Net margin −72.5% · Return on equity −32.6% · Return on assets (EBIT) −29.3% (5-year average) · Operating margin −56.4% · Revenue (TTM) A$19.3M.
Competitive moat
Our AI-assisted moat analysis scores the competitive advantage at 8 out of 100 (low confidence).
What moves the price
The share trades about 80% below its 52-week high and 21% above its 52-week low, currently below its 200-day average.
For context, the median of 10 Healthcare peers we cover trades at −9% fair-value upside, at 83%, GSS screens cheaper than that median.
Fair Value models
BearA$0.0866Fair Value A$0.1246BullA$0.1550
Price A$0.0680 · Upside +83.3%
Model ⓘEach model values the company its own way (discounted cash flow, earnings, assets, dividends). The fair value above starts from their evidence-weighted blend, not from a single model. In cyclical trough or peak years, after dilution or a stock split it is adjusted afterwards, so it can sit above or below the models.Bear ⓘBear = the cautious scenario: the same model computed with conservative anchors (lower growth, margins and valuation multiples). Together with Bull it frames a plausible valuation range, not a price target.BaseBull ⓘBull = the optimistic scenario: the same model computed with favourable anchors (higher growth, margins and valuation multiples). Together with Bear it frames a plausible valuation range, not a price target. If a model's bull case is above four times its base value, the table shows that limit with a > sign (like the overall Bull above): beyond it no assumption holds.Coverage ⓘCoverage = how well-backed THIS model's estimate is for this stock (0–100): how complete and reliable its input data are, and how well the model fits the company. The final Fair Value is an evidence-weighted blend, so better-evidenced models count more. Green ≥70, amber 50–69, grey below 50.
Growth Quality ⓘGrowth is valuable only when reinvestment earns attractive returns (Aswath Damodaran): sustainable growth depends on return on capital, reinvestment and efficiency. Basis: total company revenue over the periods shown on the cards (3Y/5Y/all years), not per share, so a merger can show up as a growth jump; per-share earnings growth is in the value-creation card.0/100
Revenue is shrinking: the last year, the last three and the last five years are all negative.
Revenue growth 1 year
−9.1%
Revenue growth 3 years ⓘMeasures the company's TOTAL revenue from reported annual statements: compound average growth per year (CAGR) from the fiscal year 3, 5 or N years back to the most recent comparable fiscal year. Not per share: buybacks do not change this number, and a merger can appear as a growth jump. Per-share growth (which does include buybacks) is in the value-creation card.
−5.2%
Revenue growth 5 years ⓘMeasures the company's TOTAL revenue from reported annual statements: compound average growth per year (CAGR) from the fiscal year 3, 5 or N years back to the most recent comparable fiscal year. Not per share: buybacks do not change this number, and a merger can appear as a growth jump. Per-share growth (which does include buybacks) is in the value-creation card.
−12.6%
Start year 2021 (pandemic). Over 10 years: +16.0% a year
Revenue growth 14 years ⓘMeasures the company's TOTAL revenue from reported annual statements: compound average growth per year (CAGR) from the fiscal year 3, 5 or N years back to the most recent comparable fiscal year. Not per share: buybacks do not change this number, and a merger can appear as a growth jump. Per-share growth (which does include buybacks) is in the value-creation card.
+34.8%
’15
’16
’17
’18
’19
’20
’21
’22
’23
’24
’25
’26
Profit margin (trend) ⓘOperating margin then vs now, from reported annual statements. A falling margin after a boom year is the classic peak-earnings signal: the growth rate then leans on an inflated base.
5.5% (2021) → −122.8% (2026)
What shareholders gained per year ⓘWe only publish this rate when it is defensible. Reason: fiscal 2026 is a loss year, no rate is defined from a loss
Price, fair value, quality and upside side by side.
Free, no sign-up
Peer GroupⓘHow this stock ranks against its industry: the green marker is this stock, the band is the typical 25–75% peer range, and the tick is the median.Diagnostics & Research · 126 stocks
Beats the industry median on 3/8 measures
Overall it trails its industry peers.
Valuation
Quality Score35 · Bottom 25%
Fair Value upside+83.2% · Top 25%
Profitability
Return on assets−36.4% · Bottom 25%
Net margin (12 months)−72.5% · Bottom 25%
Operating margin (12 months)−56.4% · Bottom 25%
Growth and dividend
Revenue growth (quarter YoY)−5.4% · Bottom 25%
Valuation Multiplesvs Diagnostics & Research median · lower = cheaper
For bloggers, editors and developers: paste this into your site or blog (a “Custom HTML” block in WordPress), it shows the current fair value and links back here. Free, plain HTML, and welcome. Full data streams (CSV/JSON) at /developers.
Is Genetic Signatures Ltd (GSS) overvalued or undervalued?
As of Nov 4, 2026, our model estimates a fair value of A$0.1246 versus a price of A$0.0680, about +83% upside (undervalued).
What is the fair value of GSS?
Our model-based fair value for Genetic Signatures Ltd is A$0.1246 (as of Nov 4, 2026), built from audited fundamentals. The current price: A$0.0680.
What is the quality score of GSS?
Genetic Signatures Ltd has a Quality Score of 35/100. It measures business quality (profitability, growth, cash flow, balance-sheet strength, investment discipline, share issuance). Market factors such as price momentum and volatility do not enter the number; they are shown separately in the detail view.
What is the price target for Genetic Signatures Ltd (GSS)?
Our model-based price target is the fair value of A$0.1246 (as of Nov 4, 2026) from 1 valuation models. Cautious scenario A$0.0866, optimistic scenario A$0.1550. It is a calculation from audited fundamentals, not an analyst target.
What is the Genetic Signatures Ltd stock forecast for 2026?
Our models put fair value at A$0.1246, about +83% upside versus a price of A$0.0680 (undervalued). Cautious scenario A$0.0866, optimistic scenario A$0.1550. The calculation is refreshed regularly with new filings.
What is the revenue of Genetic Signatures Ltd (GSS)?
Genetic Signatures Ltd reported trailing-twelve-month revenue of about A$19.3M (latest available figure, as of Nov 4, 2026).
What is the intrinsic value of Genetic Signatures Ltd (GSS)?
Intrinsic value and fair value mean the same thing: what the business is worth on its numbers, independent of the share price. For Genetic Signatures Ltd it is A$0.1246 per share (as of Nov 4, 2026), against a price of A$0.0680. It is the blended result of 1 valuation models in 1 family (Asset-Based).
Is Genetic Signatures Ltd stock overvalued or undervalued in 2026?
As of Nov 4, 2026, GSS trades below its calculated fair value: price A$0.0680, fair value A$0.1246, a gap of about +83% (undervalued). The calculation is refreshed with each new quarterly report, so the verdict can change during the year.
Is fair value the same as the market price of GSS?
No. The price is what the market pays today (A$0.0680); the fair value is what the company's own numbers justify (A$0.1246). For Genetic Signatures Ltd the two are A$0.0566 per share apart. That gap is exactly why we show both numbers side by side.
How much is Genetic Signatures Ltd worth?
The market values Genetic Signatures Ltd at about A$15.4M (market capitalisation, as of Nov 4, 2026). Per share that is A$0.0680; our models calculate a fair value of A$0.1246 per share.
What do the bullish and bearish scenarios say about GSS?
Our models span a range for Genetic Signatures Ltd: cautious scenario A$0.0866, base A$0.1246, optimistic A$0.1550 per share (as of Nov 4, 2026, price A$0.0680). The range comes from different growth and margin assumptions, not from analyst opinions.
How solid is the balance sheet of Genetic Signatures Ltd (GSS)?
Balance-sheet figures for Genetic Signatures Ltd (as of Nov 4, 2026): return on equity −32.6%. They feed the Quality Score of 35/100, which measures business quality independently of the share price.
How far is GSS from its 52-week high?
Genetic Signatures Ltd trades at A$0.0680, about 80% below its 52-week high of A$0.3350 and 21% above the low of A$0.0560 (as of Nov 9, 2026). Distance from the high says nothing about value: that is what the fair value of A$0.1246 is for.
Which stocks are comparable to Genetic Signatures Ltd?
From the same area (Healthcare) we also value Thermo Fisher Scientific Inc, Danaher Corporation, WuXi AppTec Co, Lonza Group, among others. Each of them has its own fair-value calculation on this site using the same models, so the comparison is like for like.
Is Genetic Signatures Ltd stock attractive at the current price?
The data as of Nov 4, 2026: price A$0.0680, calculated fair value A$0.1246 (+83%), Quality Score 35/100, from 1 models. Whether that fits your horizon and risk tolerance is your call. We provide the calculation, not investment advice.
How is the fair value of GSS calculated?
We run Genetic Signatures Ltd through 1 models from 1 family: Asset-Based. Every model gets the same audited fundamentals; the fair value of A$0.1246 builds on their evidence-weighted average, with the spread shown as a cautious and an optimistic scenario.
Is it still worth investing in stocks now?
The global stock market currently sits 13.3% above its aggregate fair value. Genetic Signatures Ltd currently trades 45% below its own fair value, and the market average says nothing about that. An expensive market is no reason to stay out and no reason to buy everything at once: keep a broad savings plan running, buy single stocks only with money you can do without, and hold part of your money liquid while the market is high. The full picture including sectors is on is it worth investing now.
What is the share price of Genetic Signatures Ltd (GSS)?
The closing price on Nov 9, 2026 was A$0.0680. Our model-based fair value is A$0.1246, about +83% upside (undervalued). We carry closing prices from our data provider, not a live tick.
What should I pay attention to with Genetic Signatures Ltd right now?
The large discount to fair value meets weak quality (35/100). That raises the risk this is a value trap rather than a bargain. The price is below even our cautious bear case (A$0.0866). The market is more pessimistic than our downside scenario. The large gap to fair value rests on thin data (low evidence): fewer applicable models and a shorter history. Read it with extra caution.
Key figures of Genetic Signatures Ltd
How large is the market capitalisation of Genetic Signatures Ltd (GSS)?
The market capitalisation of Genetic Signatures Ltd is A$15.4M (≈ $10.6M). The stock-market value of the whole company: share price times number of shares. It is what the market asks for the entire business today.
What is the P/S ratio of Genetic Signatures Ltd (GSS)?
The price-to-sales ratio of Genetic Signatures Ltd is 0.93 (last twelve months). Price to sales: market value relative to yearly revenue. Useful when profit is thin or distorted.
What are the earnings per share of Genetic Signatures Ltd (GSS)?
Earnings per share at Genetic Signatures Ltd are A$−0.0600. Earnings per share over the last twelve months: total profit spread across every single share.
What is the net margin of Genetic Signatures Ltd (GSS)?
The net margin of Genetic Signatures Ltd is −72.5% (last twelve months). How much of every unit of revenue ends up as profit. 10% means 10 cents of profit per dollar of sales.
What is the return on equity of Genetic Signatures Ltd (GSS)?
The return on equity (ROE) of Genetic Signatures Ltd is −32.6% (last twelve months). Profit relative to shareholders' equity, how efficiently the company works with its owners' money.
What is the EBIT return on assets of Genetic Signatures Ltd (GSS)?
On an EBIT basis the return on assets of Genetic Signatures Ltd is −29.3% (avg 5y). Operating profit (EBIT) relative to everything the company owns, as a multi-year average. It describes the business model rather than one good or bad year.
What is the operating margin of Genetic Signatures Ltd (GSS)?
The operating margin of Genetic Signatures Ltd is −56.4% (last twelve months). Profit from the core business (before interest and taxes) relative to revenue.
How fast is revenue growing at Genetic Signatures Ltd (GSS)?
Revenue at Genetic Signatures Ltd is growing −5.4% versus a year earlier (3y avg −5.2%). How much revenue grew versus a year earlier (YoY). The 3-year average next to it puts the single year in context.
How fast are earnings growing at Genetic Signatures Ltd (GSS)?
Earnings per share at Genetic Signatures Ltd are growing +3.6% versus a year earlier. How much earnings per share grew versus a year earlier.
How much free cash flow does Genetic Signatures Ltd (GSS) generate?
The free cash flow of Genetic Signatures Ltd is −A$8.8M (fiscal year 2026). The cash truly left after running and investing in the business, this is what pays dividends and buybacks.
How much net cash does Genetic Signatures Ltd (GSS) hold?
Genetic Signatures Ltd holds more cash than debt, A$8.8M net (fiscal year 2026). The company holds more cash than debt, a safety cushion.
Free · no account needed
Watch Genetic Signatures Ltd in the live analysis
One click puts Genetic Signatures Ltd on your watchlist: fair value and trend at a glance, plus comparison, the diversification check and the 27,000+ stock screener.
Thin data
Nov 4, 2026